« back to Press Releases

October 22, 2015

AgeneBio to Present at 8th Annual Clinical Trials on Alzheimer’s Disease

Scientific Leadership to Focus on Upcoming HOPE4MCI Phase 3 Trial and Proprietary AGB101 Formulation

Baltimore, MD, October 22, 2015 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced that the company will present at the 8th Clinical Trials on Alzheimer’s Disease (CTAD). The conference will be held November 5-7 in Barcelona. AgeneBio Founder and Scientific Advisor Michela Gallagher, PhD, and Vice President of Research and Development Sharon Rosenzweig-Lipson, PhD, will present on Saturday, November 7, 2015, at 11:45 am CEST.

Dr. Gallagher and Dr. Rosenzweig-Lipson will present “Clinical Trial in MCI Reducing Hippocampal Overactivity: HOPE4MCI,” AgeneBio’s upcoming Phase 3 trial designed to slow the progression to – and delay the onset of – amnestic mild cognitive impairment, the symptomatic preclinical stage of Alzheimer’s. Additionally, Dr. Rosenzweig-Lipson will present a poster entitled “Pharmacokinetic Profile of a Novel Low Dose Extended Release Formulation of AGB101 (Levetiracetam),” AgeneBio’s proprietary AGB101 formulation.

About AgeneBio
AgeneBio, Inc., is a development-stage CNS biopharmaceutical company developing innovative therapeutics aimed at preserving and restoring brain function for unserved patients afflicted with neurological and psychiatric diseases. AgeneBio’s novel pipeline of therapies is based on decades of research at Johns Hopkins University and leading research centers worldwide showing that overactivity in the hippocampus contributes to cognitive impairment and drives neurodegeneration if not controlled. This overactivity is a characteristic feature of amnestic mild cognitive impairment (aMCI), the symptomatic pre-dementia stage of Alzheimer’s disease. If approved, AgeneBio’s Phase 3-ready lead candidate AGB101 will be the first and only therapeutic targeting hippocampal overactivity and potentially the first therapeutic to slow progression to and delay the onset of Alzheimer’s dementia. AgeneBio expects to initiate the HOPE4MCI Phase 3 clinical trial of AGB101 in 2016. AgeneBio also has a novel GABA-A alpha5 small molecule program in late discovery stage with therapeutic potential for a spectrum of untreated conditions including aMCI, autism and schizophrenia. Learn more at www.agenebio.com and follow us on Twitter @AgeneBio.

Media Contacts
press@agenebio.com
Jennifer Guinan | Sage Strategic Marketing | 610.410.8111
Hilary Lefebvre | Acadia Co. | 212.300.4929